Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
With increasing overlap between advanced clear cell and non-clear cell RCC management with IO+TKI therapy, are there subtypes of non-clear cell RCC for which you would not use this approach?
Related Questions
What are your top takeaways in GU Cancers from ESMO 2024?
Do you need renal biopsy before SBRT for RCC suspicious cancer?
What are your top takeaways from ASCO GU 2025?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
What is your preferred regimen for a patient with clear cell RCC, progression after an IO+IO regimen, with a chronic non-healing wound?
Do you recommend any alternative schedule for cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
How do you manage anemia associated with belzutifan therapy?
How do you manage hypoxia induced by belzutifan?
Would you offer adjuvant immunotherapy (pembrolizumab) for chromophobe RCC with R1 resection?
